In vitro and in vivo experiments revealed that ROBO1 suppresses the proliferation and angiogenesis of CCA, while E280* nonsense mutation of ROBO1 loses the tumor-suppressing effects through interruption of the SLIT2/ROBO1 signaling pathway. This evidence concerns the gene ROBO1 and cholangiocarcinoma.